Alnylam Pharmaceuticals
ALNY
#584
Rank
C$47.69 B
Marketcap
$371.49
Share price
-0.89%
Change (1 day)
57.12%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Alnylam Pharmaceuticals (ALNY) - Total debt

Total debt on the balance sheet as of June 2024 : C$1.76 B

According to Alnylam Pharmaceuticals 's latest financial reports the company's total debt is C$1.76 B. A companyโ€™s total debt is the sum of all current and non-current debts.

Alnylam Pharmaceuticals - Total debt on balance sheet (from 2003 to 2024)

Total debt by year

Year Total debt Change
2023-12-31C$1.73 B-3.36%
2022-12-31C$1.79 B41.9%
2021-12-31C$1.26 B89.96%
2020-12-31C$0.66 B68.75%
2019-12-31C$0.39 B862.41%
2018-12-31C$40.92 M8.5%
2017-12-31C$37.71 M-81.29%
2016-12-31C$0.20 B
2007-12-31C$6.62 M-37.71%
2006-12-31C$10.63 M23.55%
2005-12-31C$8.6 M9.57%
2004-12-31C$7.85 M222.44%
2003-12-31C$2.43 M

Total debt for similar companies or competitors

Company Total debt differencediff. Country
C$0.16 B-90.94%๐Ÿ‡บ๐Ÿ‡ธ USA
C$3.66 B 107.38%๐Ÿ‡บ๐Ÿ‡ธ USA
C$1.85 B 5.08%๐Ÿ‡บ๐Ÿ‡ธ USA
C$0.36 B-79.33%๐Ÿ‡บ๐Ÿ‡ธ USA
C$0.91 M-99.95%๐Ÿ‡บ๐Ÿ‡ธ USA
C$39.31 B 2,123.44%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
C$34.53 B 1,852.96%๐Ÿ‡ซ๐Ÿ‡ท France
C$25.66 B 1,351.41%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel